Evidence map›Paper›PMID 22526531›Full record

Trial reportPsychopharmacology2012

The effects of varenicline on attention and inhibitory control among treatment-seeking smokers.

Jessica D Rhodes, Larry W Hawk, Rebecca L Ashare, Nicolas J Schlienz, Martin C Mahoney

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Psychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Pharmacological intervention and abstinence in smokers undergoing cessation treatment: A psychophysiological study.International journal of psychophysiology : official journal of the International Organization of Psychophysiology · 2018
    Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. The Role of Cognitive Control in the Self-Regulation and Reinforcement of Smoking Behavior.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019
    Review
  12. Review
  13. Review
  14. Cognitive Effects of Nicotine: Recent Progress.Current neuropharmacology · 2018
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jessica D RhodesDepartment of Psychology, University at Buffalo, 230 Park Hall, Box 604110, Buffalo, NY 14260, USA.
Larry W Hawk
Rebecca L Ashare
Nicolas J Schlienz
Martin C Mahoney

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleVarenicline represents a new class of smoking cessation aids that has different mechanisms of action that are unique from bupropion or nicotine replacement therapies. An improved understanding of these mechanisms may lead to greater treatment success in quitting smoking.

objectivesWe examined the effects of steady-state varenicline on attention and inhibitory control among adult treatment-seeking smokers.

methodsAdult smokers enrolled in a randomized clinical trial received either 4 weeks of pre-quit varenicline (n = 31) or 3 weeks of placebo (n = 26) followed by 1 week of standard varenicline treatment. Participants in the present work completed cognitive assessments at a baseline session (prior to treatment) and again 3 weeks later (during active treatment). At both sessions, participants completed the stop signal task to assess both lapses in attention and inhibitory control.

resultsAnalyses indicated that varenicline improved lapses in attention compared to placebo. There were no significant differences observed between groups at either session for inhibitory control.

conclusionsThe present study demonstrated that varenicline improves lapses in attention among treatment-seeking smokers preparing to make a quit attempt. These findings suggest that the domain of attention may be a good candidate for larger studies of the role of improved cognition in understanding the mechanisms of varenicline treatment for smoking cessation.

Indexed as

Inhibition, PsychologicalAdolescentAdultAgedAttentionBenzazepinesCognitionDrug Administration ScheduleHumansMiddle AgedNicotinic AgonistsPatient ComplianceQuinoxalinesReaction TimeSmokingSmoking CessationBenzazepinesNicotinic AgonistsQuinoxalinesVarenicline

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.